Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oxford

44.80
+2.044.77%
Post-market: 44.75-0.0500-0.11%19:30 EDT
Volume:430.98K
Turnover:19.06M
Market Cap:665.96M
PE:7.63
High:45.04
Open:42.64
Low:42.12
Close:42.76
Loading ...

Oxford Instruments price target lowered to 2,750 GBp from 2,850 GBp at Deutsche Bank

TIPRANKS
·
18 Apr

Artemis Investment Management Increases Stake in Oxford Instruments

TIPRANKS
·
17 Apr

Oxford Industries Forms New Subsidiary

MT Newswires Live
·
17 Apr

Hold Rating Justified Amid Stable Performance and Tariff Concerns for Oxford Instruments

TIPRANKS
·
16 Apr

Oxford Economics Cuts U.K. 2026 Growth Forecast to 0.9% Due to Tariff Impact -- Market Talk

Dow Jones
·
15 Apr

Artemis Increases Stake in Oxford Instruments

TIPRANKS
·
15 Apr

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

PR Newswire
·
15 Apr

Oxford Nanopore Technologies Announces LTIP and DBP Awards for Directors

TIPRANKS
·
15 Apr

Oxford Metrics Executes Share Buyback to Optimize Capital Structure

TIPRANKS
·
14 Apr

Chanel Boat Race: Who are favourites and where do Oxford and Cambridge race?

cityam
·
13 Apr

Oxford Metrics Sees Increase in Aviva’s Stake to 11%

TIPRANKS
·
11 Apr

New Research by FIS and Oxford Economics Finds That Cyberthreats, Fraud, Regulatory Complexities and Financial Inefficiencies Cost Businesses $100 Million Annually

Business Wire
·
10 Apr

Trina Solar Gets Licensing Rights for Oxford Photovoltaics' Products

MT Newswires Live
·
10 Apr

Oxford Biomedica Reports Strong 2024 Financial Performance

TIPRANKS
·
10 Apr

Tempest Therapeutics Terminates Loan Agreement with Oxford

TIPRANKS
·
10 Apr

Oxford Biomedica prepares statements on ‘going concern basis’

TIPRANKS
·
09 Apr

Oxford Biomedica reports FY24 EPS (GPB 41.75) vs. (GPB 163.11) last year

TIPRANKS
·
09 Apr

Oxford Biomedica vice chair Stuart Henderson to retire

TIPRANKS
·
09 Apr

Oxford Biomedica sees FY25 revenue GBP 160M-GBP 170M

TIPRANKS
·
09 Apr

Oxford BioMedica: Promising Growth and Attractive Valuation Drive Buy Rating

TIPRANKS
·
09 Apr